Neuroendocrine Tumor Treatment Market, by Treatment Type (Somatostatin Analogues (SSAs) (Octreotide, Lanreotide, and Others), Targeted Therapy, Chemotherapy, and Others), by Indication (Gastrointestinal NET, Lung NET, Pancreatic NET, and Other NET), by En

Neuroendocrine Tumor Treatment Market, by Treatment Type (Somatostatin Analogues (SSAs) (Octreotide, Lanreotide, and Others), Targeted Therapy, Chemotherapy, and Others), by Indication (Gastrointestinal NET, Lung NET, Pancreatic NET, and Other NET), by End User (Hospitals, Oncology Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Neuroendocrine tumors (NETs) result from the abnormal growth of neoplasms that originate from cells of various endocrine glands and nervous systems. Though most of these are benign, some tend to become malignant and may turn cancerous in the long term. Neuroendocrine tumors are generally infected initially in intestine, which are often known as carcinoid tumors. Pancreas is the second most prime organ in the body, where growth of NET is common. There are number of clinical trials are ongoing to develop the novel therapy or drugs for the treatment of the pancreatic neuroendocrine tumors in adult patients.
Market Dynamics
The rising incidence of GI and lung neuroendocrine tumors is a key factor that is expected to fuel growth of the global neuroendocrine tumor treatment market over the forecast period. For instance, according to data published in American Society of Clinical Oncology (ASCO) in 2019, estimated 12,000 people in the U.S. are diagnosed with a NET, each year. And around 170,000 people are living currently with NET. The 5-year survival for NET of the small intestine was 86.2%, 82.7% for stomach, and 67.4% for colon. Apart from GI and Lung Neuroendocrine, there are other factors, which influence NET include hormonal imbalance at pituitsary gland and thyroid gland. The rising demand for various imagining techniques in North America and Europe is expected to fuel growth of the global market over the forecast period. Drug portfolio expansion and development of new products that can inhibit excess hormone production are some of the other factors that are expected to augment growth of the global neuroendocrine tumor treatment market over the forecast period.
Key features of the study:
This report provides in-depth analysis of the neuroendocrine tumor treatment market, market size (US$ Million) and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global neuroendocrine tumor treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
Key companies covered as a part of this study include Pfizer Inc, Novartis AG, Ispen, Advanced Accelerator Applications, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc., and Exelixis, Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, end user upgrades, market expansion, and marketing tactics
The global neuroendocrine tumor treatment market report caters to various stakeholders in this industry, including investors, drug/product manufacturers, distributors and suppliers for neuroendocrine tumor treatment market, research and consulting firms, new entrants, and financial analysts
Various strategy matrices used in analyzing the neuroendocrine tumor treatment market would provide stakeholders vital inputs to make strategic decisions accordingly
Detailed Segmentation:
Global Neuroendocrine Tumor Treatment Market, By Treatment Type :
Somatostatin Analogues (SSAs)
Octreotide
Lanreotide
Others
Targeted Therapy
Chemotherapy
Others
Global Neuroendocrine Tumor Treatment Market, By Indication:
Gastrointestinal NET
Lung NET
Pancreatic NET
Other NET
Global Neuroendocrine Tumor Treatment Market, By End User:
Hospitals
Oncology Centers
Others
Global Neuroendocrine Tumor Treatment Market, By Region:
North America
By Treatment Type:
Somatostatin Analogues (SSAs)
Octreotide
Lanreotide
Others
Targeted Therapy
Chemotherapy
Others
By Indication:
Gastrointestinal NET
Lung NET
Pancreatic NET
Other NET
By End User
Hospitals
Oncology Centers
Others
By Country:
U.S.
Canada
Europe
By Treatment Type:
Somatostatin Analogues (SSAs)
Octreotide
Lanreotide
Others
Targeted Therapy
Chemotherapy
Others
By Indication:
Gastrointestinal NET
Lung NET
Pancreatic NET
Other NET
By End User
Hospitals
Oncology Centers
Others
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Treatment Type:
Somatostatin Analogues (SSAs)
Octreotide
Lanreotide
Others
Targeted Therapy
Chemotherapy
Others
By Indication:
Gastrointestinal NET
Lung NET
Pancreatic NET
Other NET
By End User
Hospitals
Oncology Centers
Others
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
Latin America
By Treatment Type:
Somatostatin Analogues (SSAs)
Octreotide
Lanreotide
Others
Targeted Therapy
Chemotherapy
Others
By Indication:
Gastrointestinal NET
Lung NET
Pancreatic NET
Other NET
By End User
Hospitals
Oncology Centers
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
By Treatment Type:
Somatostatin Analogues (SSAs)
Octreotide
Lanreotide
Others
Targeted Therapy
Chemotherapy
Others
By Indication:
Gastrointestinal NET
Lung NET
Pancreatic NET
Other NET
By End User
Hospitals
Oncology Centers
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Treatment Type:
Somatostatin Analogues (SSAs)
Octreotide
Lanreotide
Others
Targeted Therapy
Chemotherapy
Others
By Indication:
Gastrointestinal NET
Lung NET
Pancreatic NET
Other NET
By End User
Hospitals
Oncology Centers
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Pfizer Inc*
Company Overview
Drug Portfolio
Financial Performance
Key Strategies
Recent Developments
Future Plans
Novartis AG
Ispen
Advanced Accelerator Applications
Tarveda Therapeutics
Progenics Pharmaceuticals, Inc.
Hutchison Medipharma Limited
Dauntless Pharmaceuticals Inc.
Exelixis, Inc.
“*” marked represents similar segmentation in other categories in the respective section